Krystal Biotech falls as data for pipeline programs pushed to 2027

Krystal Biotech (KRYS) reported Q3 2026 net income of $63.07M ($2.05 per share), down from $79.36M ($2.66 per share) in Q3 2025, due to higher income tax expenses. Revenues rose to $127.34M, with VYJUVEK product revenue up over 30%. The company announced market expansions for VYJUVEK and clinical trial updates. KRYS stock fell 12.78%.

Krystal Biotech reported 30% YOY revenue growth for VYJUVEK, driven by expanding prescriber base and international launches. Gross margin was 94%, slightly decreased due to international markets. The company announced a $400M share repurchase program and expects international revenue to scale with upcoming launches. Clinical milestones include data readouts and FDA discussions for Gorlin syndrome and Ocular DEB programs. Management revised R&D and SG&A guidance downward to $155M-$165M.

Krystal Biotech reported Q3 revenue of $32M for VYJUVEK. Expansion in Europe includes pricing deals in Germany, Japan, and Italy, with launches expected in early 2027. Pipeline updates include promising data for KB113 in Gorlin syndrome and delays in other programs. Q3 gross margin was 94%, with adjusted expense guidance lowered to $155M-$165M. The board approved a $400M share buyback program.

Krystal Biotech reported Q3 2026 net product revenue of $127.3M, up 30% YoY, and net income of $63.1M. Operating income was $71.1M, with $1.2B in cash. The board authorized a $400M share repurchase program. VYJUVEK demand grew in the U.S., with launches expected in Europe. Clinical milestones include KB111 interim results before year-end.

Krystal Biotech (KRYS) reported Q3 GAAP EPS of $2.05, exceeding estimates by $0.28. Revenue reached $1.1B, a 1024.7% year-over-year increase, surpassing expectations by $973.46M. The company had $1.2B in cash and investments as of September 30, 2026, with product revenue at $127.3M.

Krystal Biotech reported 3Q 2026 revenue of $127.34M, up 30.2% YoY, with net income of $63.07M and EPS of $2.05, both down YoY. Growth was driven by VYJUVEK launches in Europe and Japan. The company expects pricing decisions and trial results in 2027.